Multiple Sclerosis profile updates
Test in Focus
Immunoglobulin kappa free light chain testing is an alternative, cutting-edge approach available at Mayo Clinic Laboratories to evaluate for multiple sclerosis. In this “Test in Focus” episode of the "Answers From the Lab" podcast, Maria Alice Willrich, Ph.D., explains how this first-line laboratory test, recently validated by Mayo Clinic researchers, can be used in conjunction with clinical and imaging studies to diagnose the challenging, neurodegenerative illness.
“I believe in this approach because it provides an objective, quantitative test result,” Dr. Willrich says. “And I strongly think that it translates in a significant quality improvement over manual testing in the lab. The value of better testing is translated into better answers from the lab to providers and to patients, and to all clients of the laboratory.”
Not only is the automated assay faster and cheaper than traditional oligoclonal banding testing, explains Dr. Willrich, but kappa free light chain testing provides increased sensitivity for clear results that set patients on the correct diagnostic pathway. Listen to learn more.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Both serum and spinal fluid are required. Spinal fluid must be obtained within 1 week of serum collection.
Specimen Type: Spinal fluid
Specimen Volume: 1 mL
Container/Tube: Sterile vial
Collection Instructions: Label specimen as spinal fluid.
Specimen Type: Serum
Preferred: Serum gel
Acceptable: Red top
Specimen Volume: 1 mL
Analytic time: 3 to 5 days
Days performed: Monday through Friday
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebral spinal fluid.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.